NCT02753088View on ClinicalTrials.gov

Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis

PHASE3CompletedINTERVENTIONAL
Enrollment

158

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
DRUG

BCD-063

DRUG

Copaxone-Teva

DRUG

Placebo

Sponsors

Lead Sponsor

Biocad
All Listed Sponsors
lead

Biocad

INDUSTRY